A word from the CEO: 2014 in review

2014 was an amazing year at Cortechs.ai. We experienced remarkable growth in all aspects of the company and added many significant hospitals, clinics, universities, imaging service facilities and military bases as customers. I want to warmly thank you for using NeuroQuant in your clinical and research practices.

In my role as the CEO of Cortechs.ai, I get many opportunities to speak with a range of customers – from the neurology and neuroradiology heads of the largest hospitals and clinics, to the smallest imaging services facilities, in the US and in Europe. It is always a great opportunity for me to get a first-hand impression of the state-of-the-art trends in radiology and neurology and to sense the reality and daily challenges of providing imaging healthcare services.

What I have learned this year is that quantitative imaging is getting acceptance in clinical practice and that measuring sub-cortical brain volumes and comparing them to normative values has clinical application in a growing number of clinical disciplines, from dementia, through epilepsy, multiple sclerosis, traumatic brain injuries and a variety of pediatric disorders.

Armed with great customer feedback and with growth momentum, we are getting ready to improve NeuroQuant even further to keep its leading position in the T1-weighted quantitative imaging market. This year NeuroQuant customer will enjoy a much broader set of reports highlighting more brain volumes that are relevant to the above clinical disciplines.  Additionally, we will further improve scan/re-scan accuracy, computational performance and the support of additional platforms such as Windows and Linux.

As usual, we always look for feedback and ideas for improvement and we welcome anybody that wants to share it with us.

I would like to invite you to our website (cortechs.ai) where you will find a wealth of information and scientific publications relevant to quantitative imaging.

Whether you are looking to learn and educate yourself about quantitative neuroimaging, or if you want to hear how to use it in clinical practice – we can help. Feel free to contact us.

Guri Stark
CEO
Cortechs.ai

More Resources

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.
Scroll to Top